2026 Peptide Enforcement Timeline: Every Major Action
2026 has been the most consequential year for federal enforcement against research-peptide suppliers in the modern history of the market. Here is every major action, in order.
DOJ enforcement action — company shut down
Federal agents conducted enforcement raid on operations
Federal charges filed
Reviewed BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, DSIP
Raided by USPIS, FBI, and IRS CI — website went offline
The Pattern
The enforcement actions share common characteristics. Targeted companies were operating with marketing strategies — influencer sponsorships, implied dosing guidance, before-and-after testimonials — that regulators view as inconsistent with legitimate research-only positioning. The scale of the 2021–2025 GLP-1 boom drew mainstream consumer attention to peptides, and with it, enforcement attention to the largest and most visible suppliers.
Suppliers that have continued operating through this period share a different profile: conservative compound selection, strict research-only positioning across all channels, and independent third-party testing documentation.
IQON Health — Research Peptides
Compliant from day one. Third-party tested. Research-use-only. US-based fulfillment.
Browse the catalog →Frequently Asked Questions
What peptide companies were shut down in 2026?
Peptide Sciences (DOJ, March), Amino Asylum (raided, March), Paradigm Peptides (charges, March), and Apex Peptides (raided, September).
Why are peptide companies being shut down?
Enforcement has focused on suppliers whose marketing implied human use — influencer campaigns, dosing guidance, therapeutic claims — rather than legitimate research-only operations.
Are research peptides still legal to buy?
Yes. Compliant suppliers operating with strict research-only positioning continue to ship. The enforcement targets companies whose marketing crossed the line.
For informational purposes only. Not medical or legal advice.